Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.14 USD
Change Today +0.01 / 0.47%
Volume 436.5K
CPXX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

celator pharmaceuticals inc (CPXX) Snapshot

Open
$2.11
Previous Close
$2.13
Day High
$2.19
Day Low
$2.08
52 Week High
01/12/15 - $3.53
52 Week Low
11/28/14 - $1.58
Market Cap
72.2M
Average Volume 10 Days
3.2M
EPS TTM
$-0.60
Shares Outstanding
33.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CELATOR PHARMACEUTICALS INC (CPXX)

Related News

No related news articles were found.

celator pharmaceuticals inc (CPXX) Related Businessweek News

No Related Businessweek News Found

celator pharmaceuticals inc (CPXX) Details

Celator Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies to treat cancer. Its proprietary drug ratio technology platform, CombiPlex, enables the rational design and rapid evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver enhanced anti-cancer activity. The company’s product pipeline includes CPX-351, a liposomal formulation of cytarabine:daunorubicin, which is in Phase III study for the treatment of acute myeloid leukemia; and CPX-1, a liposomal formulation of irinotecan:floxuridine that has completed Phase II study for the treatment of colorectal cancer. Its preclinical stage product candidate is CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation for vitro and vivo studies. The company was founded in 1999 and is headquartered in Ewing, New Jersey.

25 Employees
Last Reported Date: 03/17/15
Founded in 1999

celator pharmaceuticals inc (CPXX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $530.3K
Founder, President and Chief Scientific Offic...
Total Annual Compensation: $343.2K
Chief Financial Officer and Vice President
Total Annual Compensation: $354.5K
Compensation as of Fiscal Year 2014.

celator pharmaceuticals inc (CPXX) Key Developments

Celator Pharmaceuticals, Inc Announces Leukemia & Lymphoma Society Accelerates Milestone Payment Associated with the Phase 3 Study of CPX-351 in High Risk (Secondary) AML

Celator Pharmaceuticals, Inc. announced that The Leukemia & Lymphoma Society® [2] (LLS) is accelerating a portion of the final payment linked to the Phase 3 study of CPX-351 (cytarabine:daunorubicin) liposome injection, Celator's lead product candidate, for the treatment of patients with high-risk (secondary) acute myeloid leukemia (AML). LLS has moved forward payment of $400,000 originally attached to the final overall survival analysis milestone and added it to the milestone payment for induction response rate analysis, thereby increasing the payment from the original amount of $500,000 to $900,000. This brings the total LLS funding paid to date associated with the Phase 3 study to $4.9 million. The financial support provided by the LLS Therapy Acceleration Program (TAP) has been important in expediting the completion of the Phase 3, multicenter trial of CPX-351 versus conventional cytarabine plus daunorubicin in older patients with untreated high risk (secondary) AML. Enrollment in the study was completed ahead of schedule, and positive induction response results were announced earlier this month. The overall survival results, the primary endpoint of the study, are expected in the first quarter of 2016. This study is planned to support a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) expected in the second half of 2016. As part of a 2009 partnership, LLS provided $4.1 million to help fund Celator's Phase 2 clinical development program, which included two randomized, controlled studies. The positive results from those two studies were used to help design the current Phase 3 study. LLS's TAP program supports private sector and academic-based projects with the goal of advancing investigational therapies with high prospects for providing near-term benefit to patients with blood cancers.

Celator Pharmaceuticals Announces Results from Phase 3 Study of CPX-351 in Patients with High-Risk (Secondary) Acute Myeloid Leukemia

Celator Pharmaceuticals, Inc. announced final induction response rate results (complete remission plus complete remission with incomplete hematologic recovery, or CR+CRi) in the Phase 3 study comparing CPX-351 (cytarabine:daunorubicin) liposome injection to the standard of care regimen, referred to as 7+3 (conventional cytarabine and daunorubicin treatment), in patients with untreated high-risk (secondary) acute myeloid leukemia (AML). The results showed that CPX-351 produced a relative improvement in induction response rate of 43.2% (47.7% for CPX-351 vs. 33.3% for the 7+3 regimen). Data on overall survival, the primary endpoint, are expected in the first quarter of 2016. However, induction response rate is a key secondary endpoint in the study and has been an important surrogate of overall survival and clinical benefit in this patient population. These data validate the induction response rates observed in the Phase 2 study, which was associated with a marked improvement in overall survival. The randomized, controlled, Phase 3 study evaluated 309 patients, aged 60-75 years, from 39 clinical centers in the U.S. and Canada, with untreated high-risk (secondary) AML. Patients were randomized 1:1 to receive either CPX-351 or the 7+3 regimen. In addition to induction response and overall survival, other important information, such as rate of morphologic leukemia-free state, best overall response, response duration, event-free survival, and early mortality, as well as pharmacoeconomic comparisons, will be assessed and available at the conclusion of the study. The Leukemia & Lymphoma Society has partnered with Celator in the development of CPX-351.

Celator Pharmaceuticals, Inc. - Special Call

To discuss the induction response results from its Phase 3 study

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CPXX:US $2.14 USD +0.01

CPXX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CPXX.
View Industry Companies
 

Industry Analysis

CPXX

Industry Average

Valuation CPXX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELATOR PHARMACEUTICALS INC, please visit www.celatorpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.